Disentangling the Impact of Adiposity From Insulin Resistance in Heart Failure With Preserved Ejection Fraction

Yogesh N V Reddy1, Robert P Frantz2, Anna R Hemnes3

  • 1Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: https://twitter.com/yreddyhf.

Insights

Excess body fat, not diabetes, independently worsens heart failure with preserved ejection fraction (HFpEF) by increasing pulmonary capillary wedge pressure. This highlights the need for managing adiposity in HFpEF patients, even those with a normal body mass index (BMI).

Area of Science:

  • Cardiology
  • Metabolic Diseases
  • Pulmonary Hypertension

Background:

  • Obesity, insulin resistance (IR), and diabetes are prevalent in heart failure with preserved ejection fraction (HFpEF).
  • Their independent contributions to HFpEF severity are not well understood.

Purpose of the Study:

  • To determine the distinct contributions of diabetes versus obesity to left heart abnormalities in HFpEF.
  • To investigate the relationship between adiposity, IR, and hemodynamic parameters in HFpEF.

Main Methods:

  • Assessed adiposity (BMI, fat mass, waist circumference) and IR (HOMA-IR) in HFpEF patients.
  • Compared rest and exercise pulmonary capillary wedge pressure (PCWP) stratified by obesity, IR, and diabetes status.
  • Validated findings in an independent HFpEF cohort.

Main Results:

  • Obesity, irrespective of IR, was linked to greater biventricular enlargement, poorer exercise performance, and higher PCWP.
  • Increased adiposity (fat mass, BMI, waist circumference) correlated with elevated rest and exercise PCWP.
  • IR and diabetes diagnosis were not independently associated with worse cardiac remodeling or hemodynamics.

Conclusions:

  • Excess adiposity, not IR or diabetes, is independently associated with worse hemodynamics and functional impairment in HFpEF.
  • Diabetes may serve as a marker for greater adiposity rather than a direct driver of HFpEF severity.
  • Further research into cardiometabolic therapies for HFpEF patients with excess adiposity, even below a BMI of 30 kg/m², is warranted.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
298
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
329
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
284